These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21999802)

  • 1. Editorial comment on '5 year experience with incobotulinumtoxinA (Xeomin(®) ) the first botulinum toxin drug free of complexing proteins'.
    Aoki KR
    Eur J Neurol; 2012 Mar; 19(3):355-6. PubMed ID: 21999802
    [No Abstract]   [Full Text] [Related]  

  • 2. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on the use of botulinum toxin.
    Moore AP
    Eur J Neurol; 2012 Mar; 19(3):357-8. PubMed ID: 22040329
    [No Abstract]   [Full Text] [Related]  

  • 4. IncobotulinumtoxinA in esthetics.
    Kerscher M; Yutskovskaya Y; Flynn TC
    J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xeomin is free from complexing proteins.
    Frevert J
    Toxicon; 2009 Oct; 54(5):697-701. PubMed ID: 19292989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin and human serum albumin.
    Malhotra R; Huilgol SC; Selva D
    Arch Ophthalmol; 2003 Nov; 121(11):1661; discussion 1661-2. PubMed ID: 14609937
    [No Abstract]   [Full Text] [Related]  

  • 8. Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
    Shome D; Kapoor R; Khare S
    J Cosmet Dermatol; 2019 Dec; 18(6):1635-1641. PubMed ID: 31135088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.
    Dressler D; Mander G; Fink K
    J Neural Transm (Vienna); 2012 Jan; 119(1):13-5. PubMed ID: 21971766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Fulford-Smith A; Gallagher CJ; Brin MF
    Dermatol Surg; 2013 Jul; 39(7):1118-9. PubMed ID: 23725480
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm".
    Giacometti J; Yen MT
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):76-7. PubMed ID: 24398499
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm".
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):77. PubMed ID: 24398500
    [No Abstract]   [Full Text] [Related]  

  • 15. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IncobotulinumtoxinA and Deep Brain Stimulation.
    Soh D; Fasano A
    Can J Neurol Sci; 2019 Sep; 46(5):603-606. PubMed ID: 31196241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].
    Kurenkov AL; Klochkova OA; Bursagova BI; Karimova HM; Kuzenkova LM; Mamedyarov AM; Namazova-Baranova LS; Agranovich OV; Agranovich AO; Soboleva OA; Khapaeva MM; Batysheva TT; Sarzhina MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):37-44. PubMed ID: 29265085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysport.
    Markey AC
    Dermatol Clin; 2004 Apr; 22(2):213-9. PubMed ID: 15222582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin for UES dysfunction: therapy or poison?
    Ravich WJ
    Dysphagia; 2001; 16(3):168-70. PubMed ID: 11453561
    [No Abstract]   [Full Text] [Related]  

  • 20. Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA.
    Ricciardi L; Ialongo T; Guidubaldi A; Di Giacopo R; Bentivoglio AR
    Parkinsonism Relat Disord; 2014 Jun; 20(6):665-7. PubMed ID: 24685658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.